Yesterday, Sept. 2, 2015, 92 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $34.60 to $483,696,928,500.00.

Highlighted Stocks Traded by Insiders:

Syntel (SYNT) - FREE Research Report

Ray Raja, who is Senior Vice President at Syntel, sold 1,176 shares at $42.66 on Sept. 2, 2015. Following this transaction, the Senior Vice President owned 11,074 shares meaning that the stake was reduced by 9.6% with the 1,176-share transaction.

The shares most recently traded at $43.19, up $0.53, or 1.23% since the insider transaction. Historical insider transactions for Syntel go as follows:

  • 4-Week # shares sold: 9,718
  • 12-Week # shares sold: 9,718
  • 24-Week # shares sold: 35,718

The average volume for Syntel has been 235,500 shares per day over the past 30 days. Syntel has a market cap of $3.6 billion and is part of the technology sector and computer software & services industry. Shares are down 3.8% year-to-date as of the close of trading on Wednesday.

Syntel, Inc. provides digital transformation, information technology (IT), and knowledge process outsourcing (KPO) services worldwide. The company operates through Banking and Financial Services; Healthcare and Life Sciences; Insurance; Retail, Logistics and Telecom; and Manufacturing segments. The company has a P/E ratio of 15.5. Currently, there are 6 analysts who rate Syntel a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SYNT - FREE

TheStreet Quant Ratings rates Syntel as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in net income and good cash flow from operations. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Syntel Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Core Molding Technologies (CMT) - FREE Research Report

Hellmold Ralph O, who is Director at Core Molding Technologies, sold 5,957 shares at $21.90 on Sept. 2, 2015. Following this transaction, the Director owned 10,604 shares meaning that the stake was reduced by 35.97% with the 5,957-share transaction.

The shares most recently traded at $19.92, down $1.98, or 9.94% since the insider transaction. Historical insider transactions for Core Molding Technologies go as follows:

  • 4-Week # shares bought: 750
  • 4-Week # shares sold: 9,000
  • 12-Week # shares bought: 750
  • 12-Week # shares sold: 9,000
  • 24-Week # shares bought: 750
  • 24-Week # shares sold: 71,320

The average volume for Core Molding Technologies has been 107,700 shares per day over the past 30 days. Core Molding Technologies has a market cap of $154.3 million and is part of the consumer goods sector and consumer non-durables industry. Shares are up 43.07% year-to-date as of the close of trading on Wednesday.

Core Molding Technologies, Inc., together with its subsidiaries, manufactures sheet molding compounds (SMC) and molds fiberglass reinforced plastics. The company has a P/E ratio of 12.4. Currently, there are no analysts who rate Core Molding Technologies a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CMT - FREE

TheStreet Quant Ratings rates Core Molding Technologies as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full Core Molding Technologies Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Epizyme (EPZM) - FREE Research Report

Ho Peter Tai-Ching, who is Chief Development Officer at Epizyme, bought 522 shares at $17.00 on Sept. 2, 2015. Following this transaction, the Chief Development Officer owned 3,522 shares meaning that the stake was boosted by 17.4% with the 522-share transaction.

The shares most recently traded at $20.48, up $3.48, or 16.99% since the insider transaction. Historical insider transactions for Epizyme go as follows:

  • 4-Week # shares bought: 2,000
  • 4-Week # shares sold: 388,584
  • 12-Week # shares bought: 2,000
  • 12-Week # shares sold: 388,584
  • 24-Week # shares bought: 2,000
  • 24-Week # shares sold: 388,584

The average volume for Epizyme has been 550,200 shares per day over the past 30 days. Epizyme has a market cap of $811.3 million and is part of the health care sector and drugs industry. Shares are up 9.33% year-to-date as of the close of trading on Wednesday.

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies for cancer patients. Its proprietary product platform creates small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases (HMTs). Currently, there are 3 analysts who rate Epizyme a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on EPZM - FREE

TheStreet Quant Ratings rates Epizyme as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full Epizyme Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.